{
  "meta": {
    "title": "35_Antiretroviral_Drugs",
    "url": "https://brainandscalpel.vercel.app/35-antiretroviral-drugs-2d31a1c8.html",
    "scrapedAt": "2025-11-30T12:34:21.413Z"
  },
  "questions": [
    {
      "text": "Which class of antiretroviral drugs does nevirapine belong to?",
      "choices": [
        {
          "id": 1,
          "text": "Nucleoside reverse transcriptase inhibitors"
        },
        {
          "id": 2,
          "text": "Non-nucleoside reverse transcriptase inhibitors"
        },
        {
          "id": 3,
          "text": "Nucleotide reverse transcriptase inhibitors"
        },
        {
          "id": 4,
          "text": "Protease inhibitors"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Nevirapine</strong> is a <strong>non-nucleoside reverse transcriptase inhibitor</strong> (NNRTI)</p>\n<p>US FDA has approved doravirine, a new non-nucleoside reverse transcriptase inhibitor(NNRTI) for the treatment of adults with HIV-1 infection given in combination with other ARTs.</p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6435",
      "difficulty": "easy"
    },
    {
      "text": "Resistance to zidovudine develops due to:",
      "choices": [
        {
          "id": 1,
          "text": "Increased efflux of the drug from nucleus"
        },
        {
          "id": 2,
          "text": "Mutations of reverse transcriptase"
        },
        {
          "id": 3,
          "text": "Increased efflux of the drug from inside the cell"
        },
        {
          "id": 4,
          "text": "Decreased zidovudine triphosphate formation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Resistance</strong> to <strong>zidovudine</strong> occurs due to <strong>mutations</strong> in the<strong> reverse transcriptase enzyme.</strong></p>\n<p>The mutations are referred to as <strong>thymidine analog mutations</strong> (TAM) because of their ability to confer <strong>cross-resistance</strong> to other thymidine analogs such as stavudine.</p>\n<p><strong>M184V mutation,</strong> which is associated with the use of lamivudine or emtricitabine, <strong>restores zidovudine susceptibility</strong> in zidovudine-resistant HIV.</p><p>The FDA recently approved <strong>fostemsavir</strong>, a new type of antiretroviral medication for adults living with HIV who cannot be treated successfully with other therapies because of resistance, intolerance, or safety considerations. The drug acts by attaching to the GP-120 protein on the outer surface of HIV and blocks HIV from infecting the CD4 cells.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6428",
      "difficulty": "medium"
    },
    {
      "text": "A patient diagnosed with AIDS is planned to be started on a lamivudine-based-antiretroviral therapy. Which of the following drugs will you not add to her regimen?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine"
        },
        {
          "id": 2,
          "text": "Stavudine"
        },
        {
          "id": 3,
          "text": "Emtricitabine"
        },
        {
          "id": 4,
          "text": "Abacavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Lamivudine</strong> and <strong>emtricitabine</strong> are <strong>not combined</strong> because of similar actions and <strong>no added benefits.</strong> Emtricitabine is a cytidine analog. It is chemically related to lamivudine and shares most of its pharmacodynamic characteristics.</p>\n<p>The same holds good for the <strong>zidovudine and stavudine</strong> combination. Zidovudine and stavudine are thymidine analogues. In fact, efficacy may even decrease because of competition for a similar activation process.</p><p>World AIDS Day is observed every year on December 1 to spread awareness about AIDS caused by Human Immunodeficiency Virus and support those who are affected by it. On December 1, 1988, the first-ever World AIDS Day was marked. This year, the World Health Organization (WHO) has announced the theme 'let communities lead', emphasizing the role of communities in addressing the challenges associated with HIV/AIDS.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6430",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements about lamivudine is false?",
      "choices": [
        {
          "id": 1,
          "text": "It is an effective agent for  patients with chronic hepatitis B"
        },
        {
          "id": 2,
          "text": "Dose is lower for blocking HIV replication than HBV replication"
        },
        {
          "id": 3,
          "text": "Should not be used as monotherapy in HBV/HIV infected patients"
        },
        {
          "id": 4,
          "text": "Anti-HBe seroconversion occurs in a minority of the patients"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>daily dose</strong>&nbsp;of lamivudine indicated for <strong>HIV (300 mg) </strong>is<strong> higher than </strong>that of the dose indicated for<strong> HBV (100 mg).</strong></p>\n<p>Lamivudine has <strong>both anti-HIV</strong> and <strong>anti-HBV</strong> activity and is an <strong>effective</strong> agent for patients with <strong>chronic hepatitis</strong> <strong>B</strong>. It should not be used alone because resistance can rapidly emerge in HIV viruses.</p>\n<p>Anti-HBe seroconversion occurs in only a minority of the patients taking lamivudine.</p>\n<p>Drugs that cause anti-HBe seroconversion:</p>\n<ul>\n<li>Lamivudine</li>\n<li>Entecavir</li>\n<li>Adefovir</li>\n<li>Tenofovir</li>\n<li>Telbivudine</li>\n<li>Pegylated interferon</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6431",
      "difficulty": "medium"
    },
    {
      "text": "A patient on antiretroviral therapy presents with severe tingling and numbness in the legs. On examination, you find that his tendon reflexes are reduced. Which of the following drugs has the highest propensity to cause this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine"
        },
        {
          "id": 2,
          "text": "Lamivudine"
        },
        {
          "id": 3,
          "text": "Stavudine"
        },
        {
          "id": 4,
          "text": "Didanosine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The scenario is suggestive of peripheral neuropathy. The drug causing<strong> maximum peripheral neuropathy </strong>is<strong> stavudine.</strong></p>\n<p>The incidence of peripheral neuropathy is very rare with both zidovudine and lamivudine. <strong>Lamivudine</strong>&nbsp;is considered one of the<strong>&nbsp;least toxic</strong> antiretroviral agents.</p>\n<p>Didanosine is frequently associated with peripheral neuropathy, but stavudine is associated with the highest risk of peripheral neuropathy.</p>\n<p>Note:<strong> Zalcitabine&nbsp;</strong>was&nbsp;associated with a&nbsp;<strong>higher incidence&nbsp;</strong>of peripheral neuropathy. It&nbsp;is no longer marketed.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6454",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs are not protease inhibitors?<div class='question-desc-html'><ol>\n<li>Nelfinavir</li>\n<li>Saquinavir</li>\n<li>Abacavir</li>\n<li>Ritonavir</li>\n<li>Raltegravir</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1 and 3"
        },
        {
          "id": 2,
          "text": "2 and 4"
        },
        {
          "id": 3,
          "text": "3 and 5"
        },
        {
          "id": 4,
          "text": "1 and 5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Abacavir </strong>is a guanosine analogue and is a <strong>nucleoside reverse transcriptase inhibitor.</strong></p>\n<p><strong>Raltegravir </strong>is an<strong> integrase inhibitor.</strong></p>\n<p>Nelfinavir, saquinavir and ritonavir are protease inhibitors.</p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6434",
      "difficulty": "easy"
    },
    {
      "text": "During a clinical trial, it was noted that the bioavailability of some drugs was substantially improved on ritonavir administration. Which of the following drugs does not exhibit this property?",
      "choices": [
        {
          "id": 1,
          "text": "Saquinavir"
        },
        {
          "id": 2,
          "text": "Lopinavir"
        },
        {
          "id": 3,
          "text": "Nelfinavir"
        },
        {
          "id": 4,
          "text": "Darunavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The bioavailability of <strong>nelfinavir</strong> is <strong>not</strong> substantially <strong>improved with ritonavir</strong> administration because it undergoes metabolism primarily by<strong> CYP2C19 </strong>and <strong>ritonavir</strong> is a <strong>weak inhibitor</strong> of CYP2C19.</p>\n<p>All other protease inhibitors undergo hepatic oxidative&nbsp;metabolism predominantly by the<strong> CYP3A4 </strong>enzyme.&nbsp;<strong>Ritonavir</strong>, being a potent inhibitor of CYP3A4 acts as a <strong>pharmacological booster</strong>&nbsp;in combination&nbsp;with other protease inhibitors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6440",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a pharmacological booster with no antiretroviral activity?",
      "choices": [
        {
          "id": 1,
          "text": "Ritonavir"
        },
        {
          "id": 2,
          "text": "Vorinostat"
        },
        {
          "id": 3,
          "text": "Belinostat"
        },
        {
          "id": 4,
          "text": "Cobicistat"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Cobicistat</strong> is a pharmacological booster with <strong>no antiretroviral activity</strong>.</p>\n<p>Cobicistat is a <strong>ritonavir analog</strong> developed as an exclusive <strong>pharmacological booster</strong> that <strong>inhibits</strong> the<strong> CYP3A4 enzyme</strong> and has no antiviral activity. It is&nbsp;available only in combination with atazanavir or darunavir or elvitegravir for HIV infections.</p>\n<p>Ritonavir is also used as a pharmacological booster but it has antiretroviral activity.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Cobicistat</strong></td>\n<td><strong>Ritonavir</strong></td>\n</tr>\n<tr>\n<td>Specific CYP3A4 inhibition</td>\n<td>\n<p>Potent inhibitor of CYP3A4 and weak inhibitor of CYP2D6</p>\n</td>\n</tr>\n<tr>\n<td>Better tolerated</td>\n<td>Less tolerated&nbsp;</td>\n</tr>\n<tr>\n<td>Reduced impact on plasma lipds</td>\n<td>Causes dose-dependent elevation in serum total cholesterol and <br />triglycerides</td>\n</tr>\n<tr>\n<td>Lacks P450 enzyme induction</td>\n<td>Moderate inducer of P450 enzymes</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;Vorinostat and belinostat are <strong>histone deacetylase inhibitors</strong>.&nbsp;Vorinostat is approved for the treatment of patients with cutaneous T-cell lymphoma with persistent or recurrent disease after two systemic therapies.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6441",
      "difficulty": "medium"
    },
    {
      "text": "The antiviral drug having dual antiviral activity against HIV and HBV is:",
      "choices": [
        {
          "id": 1,
          "text": "Enfuviritide"
        },
        {
          "id": 2,
          "text": "Abacavir"
        },
        {
          "id": 3,
          "text": "Emtricitabine"
        },
        {
          "id": 4,
          "text": "Ritonavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Antiviral</strong> drug having <strong>dual antiviral activity</strong> against <strong>HIV</strong> and <strong>HBV</strong> is <strong>emtricitabine</strong>.</p>\n<p>It is a <strong>nucleoside reverse transcriptase inhibitor</strong> similar to lamivudine. It has activity against HIV-1, HIV-2, and HBV.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6446",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a subcutaneously administered drug, that will be helpful in a patient showing high viral load despite good compliance with ART?",
      "choices": [
        {
          "id": 1,
          "text": "Maraviroc"
        },
        {
          "id": 2,
          "text": "Enfuvirtide"
        },
        {
          "id": 3,
          "text": "Raltegravir"
        },
        {
          "id": 4,
          "text": "Emtricitabine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug described in this case is <strong>enfuvirtide</strong>, which<strong>&nbsp;</strong>is an anti-HIV drug that is <strong>administered subcutaneously.</strong></p>\n<p class=\"p1\">It is used only in the treatment of those who have evidence of HIV replication (high viral load) despite ongoing antiretroviral therapy.</p>\n<p class=\"p1\">It <strong>binds to&nbsp;the gp41 subunit</strong> of the viral envelope and <strong>prevents the fusion </strong>of the virus to the cellular membranes thereby preventing entry of the virus.</p>\n<p class=\"p1\">Enfuvirtide is active against<strong> HIV-1 only</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6447",
      "difficulty": "medium"
    },
    {
      "text": "A patient showing treatment failure with multiple antiretroviral drugs is now started on maraviroc. This drug acts against:",
      "choices": [
        {
          "id": 1,
          "text": "CCR5"
        },
        {
          "id": 2,
          "text": "CXCR4"
        },
        {
          "id": 3,
          "text": "CD4"
        },
        {
          "id": 4,
          "text": "CCR5 and CD4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Maraviroc</strong> is a<strong> chemokine receptor antagonist </strong>acting against the <strong>CCR5 receptor</strong>.</p>\n<p>It&nbsp;binds to the host cell CCR-5 receptor and prevents the binding of viral GP-120 to host cells. It is indicated in patients with evidence of infection with predominantly CCR-5 tropic virus.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6449",
      "difficulty": "easy"
    },
    {
      "text": "The husband of an AIDS patient noticed that his wife had become forgetful and confused lately. She complained of dizziness and lack of sleep. Eventually, she started behaving bizarrely, paranoid that everybody is trying to kill her. Yesterday she was found in her room talking to somebody who did not exist in reality. Which of the following drugs is most commonly associated with this side effect?",
      "choices": [
        {
          "id": 1,
          "text": "Nevirapine"
        },
        {
          "id": 2,
          "text": "Efavirenz"
        },
        {
          "id": 3,
          "text": "Etravirine"
        },
        {
          "id": 4,
          "text": "Delavirdine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario describes <strong>psychiatric</strong> or<strong> CNS adverse effects</strong>, which are commonly seen with <strong>efavirenz</strong>.</p>\n<p>The CNS/ <strong>psychiatric adverse effects</strong> seen with the use of <strong>efavirenz</strong> are:</p>\n<ul>\n<li>Frank psychosis (depression, hallucinations, and/or mania)&nbsp;</li>\n<li>Impaired concentration</li>\n<li>Dysphoria&nbsp;</li>\n<li>Dizziness</li>\n<li>Vivid dreams</li>\n<li>Insomnia</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6451",
      "difficulty": "medium"
    },
    {
      "text": "A patient presenting with low-grade fever and weight loss of 3 months is diagnosed to have HIV-2 infection. Which of the following drugs is not indicated here?",
      "choices": [
        {
          "id": 1,
          "text": "Ritonavir"
        },
        {
          "id": 2,
          "text": "Tenofovir"
        },
        {
          "id": 3,
          "text": "Efavirenz"
        },
        {
          "id": 4,
          "text": "Zalcitabine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Efavirenz</strong> is not indicated for HIV-2 infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).</p>\n<p>NNRTIs are HIV-1 specific and have no activity against HIV-2. The binding site for <strong>NNRTI</strong> is virus <strong>strain-specific</strong> which only <strong>inhibits</strong> the <strong>HIV-1 reverse transcriptase.</strong> It is <strong>approved only</strong> for<strong> HIV-1 infections</strong> and should not be used for HIV-2 infections.</p>\n<p>Ritonavir, tenofovir, and zalcitabine are indicated for HIV-2 infections.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6452",
      "difficulty": "medium"
    },
    {
      "text": "A 52-year-old man who has been on ART for the past two months presents with abdominal pain. On evaluation, he was found to have acute pancreatitis. Which of the following drugs is associated with the highest risk for causing this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Didanosine"
        },
        {
          "id": 2,
          "text": "Lamivudine"
        },
        {
          "id": 3,
          "text": "Zidovudine"
        },
        {
          "id": 4,
          "text": "Abacavir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The<strong> maximum risk </strong>of<strong> pancreatitis </strong>is seen with <strong>didanosine. </strong></p>\n<p>It&nbsp;should, therefore not be combined with hydroxyurea, alcohol, or pentamidine.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6455",
      "difficulty": "easy"
    },
    {
      "text": "A patient diagnosed with AIDS is initiated on antiretroviral therapy with zidovudine. Which of the following side effects is he most likely to develop?",
      "choices": [
        {
          "id": 1,
          "text": "Anemia"
        },
        {
          "id": 2,
          "text": "Peripheral neuropathy"
        },
        {
          "id": 3,
          "text": "Lactic acidosis"
        },
        {
          "id": 4,
          "text": "Hepatotoxicity"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>This patient is most likely to develop <strong>anemia</strong> since it is the most common side effect of<strong> zidovudine</strong>.</p>\n<p><strong>Higher dosages </strong>of zidovudine lead to <strong>bone marrow suppression</strong> resulting in anemia and granulocytopenia.</p>\n<p>Peripheral neuropathy, hepatotoxicity, and lactic acidosis are rare side effects of zidovudine. </p><p>On 1 December, World AIDS Day 2024, WHO joins partners and communities under the theme <strong>“Take the rights path: My health, my right!”</strong> With human rights at the center and communities leading the way, WHO calls on global leaders and citizens to address the inequalities that hinder progress in ending AIDS. By protecting everyone’s rights, the world can end AIDS as a public health threat by 2030.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6457",
      "difficulty": "medium"
    },
    {
      "text": "Of all the nucleoside reverse transcriptase inhibitors, the use of which of the following is most strongly associated with fat wasting?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine"
        },
        {
          "id": 2,
          "text": "Lamivudine"
        },
        {
          "id": 3,
          "text": "Stavudine"
        },
        {
          "id": 4,
          "text": "Abacavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Of all the nucleoside reverse transcriptase inhibitors, the<strong>&nbsp;</strong>use of<strong> stavudine</strong>&nbsp;is most&nbsp;strongly&nbsp;associated with <strong>fat wasting</strong> (lipoatrophy).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6458",
      "difficulty": "medium"
    },
    {
      "text": "A patient on antiretroviral therapy comes to you for follow-up. His lipid profile reveals high cholesterol levels. Which of the following drugs is not associated with this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Atazanavir"
        },
        {
          "id": 2,
          "text": "Saquinavir"
        },
        {
          "id": 3,
          "text": "Amprenavir"
        },
        {
          "id": 4,
          "text": "Nelfinavir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Atazanavir</strong> is not associated with dyslipidemia, fat redistribution, or metabolic syndrome. This is in contrast to all the other protease inhibitors, which causes side effects like <strong>hypertriglyceridemia</strong>, <strong>hypercholesterolemia</strong> and other signs of <strong>lipodystrophy</strong>. </p>\n<p> Patients treated with <strong>atazanavir</strong> have significantly <strong>lower fasting triglyceride</strong> and <strong>cholesterol</strong> concentrations than patients treated with nelfinavir and lopinavir. Clinically, when <strong>abacavir</strong> (Nucleoside Reverse Transcriptase Inhibitors) is substituted for protease inhibitors in patients having dyslipidemia, it leads to an i<strong>mprovement in lipid profile</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6459",
      "difficulty": "medium"
    },
    {
      "text": "A 48-year-old known hemophiliac on antiretroviral therapy suddenly developed headache, vomiting and altered consciousness and was rushed to a hospital. Which of the following protease inhibitors is implicated here?",
      "choices": [
        {
          "id": 1,
          "text": "Saquinavir"
        },
        {
          "id": 2,
          "text": "Ritonavir"
        },
        {
          "id": 3,
          "text": "Tipranavir"
        },
        {
          "id": 4,
          "text": "Indinavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario is suggestive of <strong>intracranial hemorrhage</strong> and the protease inhibitor that is associated with this condition is<strong> tipranavir</strong>. It is a non-peptidic protease inhibitor</p>\n<p class=\"p1\">Tipranavir use has been associated rarely with intracranial hemorrhage (including fatalities) and <strong>bleeding episodes</strong> in patients with<strong> hemophilia</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6461",
      "difficulty": "medium"
    },
    {
      "text": "A patient on antiretroviral therapy comes for regular follow-up. You note nail changes as shown below. Which of the following drugs causes this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Abacavir"
        },
        {
          "id": 2,
          "text": "Ritonavir"
        },
        {
          "id": 3,
          "text": "Zidovudine"
        },
        {
          "id": 4,
          "text": "Didanosine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image shows <strong>nail hyperpigmentation</strong> and it is commonly encountered with the use of zidovudine. This is seen with <strong>c</strong><strong>hronic zidovudine administration.&nbsp;</strong></p>\n<p>The <strong>adverse effects</strong> of <strong>zidovudine</strong> are:</p>\n<ul>\n<li>Fatigue, malaise, myalgia, and anorexia</li>\n<li>Headache and insomnia</li>\n<li>Erythrocytic macrocytosis</li>\n<li>Nail hyperpigmentation</li>\n<li>Myopathy</li>\n<li>Bone marrow suppression - anemia and granulocytopenia</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/76b1fcce32a14af98378f43320c5ca9e.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6464",
      "difficulty": "medium"
    },
    {
      "text": "Which is the only antiretroviral drug that may have teratogenic properties?",
      "choices": [
        {
          "id": 1,
          "text": "Didanosine"
        },
        {
          "id": 2,
          "text": "Emtricitabine"
        },
        {
          "id": 3,
          "text": "Efavirenz"
        },
        {
          "id": 4,
          "text": "Nevirapine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The only antiretroviral drug that may have <strong>teratogenic</strong> properties is <strong>efavirenz.&nbsp;</strong></p>\n<p>It has shown teratogenicity in primates.&nbsp;However, clinical trials have suggested that there is no significantly increased risk of teratogenicity in humans as compared to other antiretroviral drugs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6466",
      "difficulty": "medium"
    },
    {
      "text": "A patient undergoing treatment for HIV complains of dizziness. On examination, you note his supine BP to be 140/80 mmHg and standing BP to be 110/70 mmHg. Which of the following drugs would have caused this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Maraviroc"
        },
        {
          "id": 2,
          "text": "Raltegravir"
        },
        {
          "id": 3,
          "text": "Enfuvirtide"
        },
        {
          "id": 4,
          "text": "Nelfinavir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario depicts a case of <strong>orthostatic hypotension</strong> and <strong>maraviroc</strong> is associated with <strong>dose-dependent</strong> and <strong>concentration-dependent</strong> orthostatic hypotension.</p>\n<p>Maraviroc is a chemokine receptor antagonist acting against the <strong>CCR5 receptor</strong>. It binds to the host cell CCR-5 receptor and prevents the binding of viral GP-120 to host cells. It is indicated in patients with evidence of infection with predominantly CCR-5 tropic virus.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4199",
      "difficulty": "hard"
    },
    {
      "text": "The ECG of a patient on antiretroviral therapy is shown below. You observe that the QTc = 477 ms. This can be attributed to:",
      "choices": [
        {
          "id": 1,
          "text": "Raltegravir"
        },
        {
          "id": 2,
          "text": "Rilpivirine"
        },
        {
          "id": 3,
          "text": "Etravirine"
        },
        {
          "id": 4,
          "text": "Efavirenz"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given ECG indicates <strong>QT interval prolongation</strong> (normal QTc = 440ms) and this is observed with the use of <strong>rilpivirine. </strong>It is a non-nucleoside reverse transcriptase inhibitor (<strong>NNRTI</strong>).<strong>&nbsp;</strong></p>\n<p>Qtc interval prolongation is observed with higher concentrations of the drug. Caution has to be exercised when rilpivirine is administered along with <strong>CYP3A4 inhibitors</strong> that can<strong> increase</strong> the<strong> concentration </strong>of rilpivirine.</p><hr><h3>Related Pearl: Drugs causing QT prolongation and torsades de pointes</h3><p>Drugs Associated with QT Prolongation and Torsades de Pointes:</p>\n<p>Antiarrhythmics:</p>\n<ul>\n<li>Sotalol</li>\n<li>Amiodarone</li>\n<li>Quinidine</li>\n<li>Procainamide</li>\n<li>Dofetilide</li>\n<li>Ibutilide</li>\n</ul>\n<p>Antimicrobials:</p>\n<ul>\n<li>Levofloxacin</li>\n<li>Ciprofloxacin</li>\n<li>Gatifloxacin</li>\n<li>Moxifloxacin</li>\n<li>Clarithromycin</li>\n<li>Erythromycin</li>\n<li>Ketoconazole</li>\n<li>Itraconazole</li>\n<li>Rilpivirine</li>\n</ul>\n<p>Antidepressants:</p>\n<ul>\n<li>Amitriptyline</li>\n<li>Desipramine</li>\n<li>Imipramine</li>\n<li>Doxepin</li>\n<li>Fluoxetine</li>\n<li>Sertraline</li>\n<li>Venlafaxine</li>\n</ul>\n<p>Antipsychotics:</p>\n<ul>\n<li>Haloperidol</li>\n<li>Droperidol</li>\n<li>Quetiapine</li>\n<li>Ziprasidone</li>\n<li>Thioridazine</li>\n</ul>\n<p>Others:</p>\n<ul>\n<li>Cisapride</li>\n<li>Sumatriptan</li>\n<li>Zolmitriptan</li>\n<li>Arsenic</li>\n<li>Dolasetron</li>\n<li>Methadone<br />&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/ef1e9f9f002544b5a2a453e8aa910ce3.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4200",
      "difficulty": "hard"
    },
    {
      "text": "A 45-year-old HIV-positive man was started on HAART. On follow-up testing, his CD4 cell count had decreased below 200/mm³. Subsequently, he developed diarrhea and redistribution of body fat. What is false about the causative drug class?",
      "choices": [
        {
          "id": 1,
          "text": "Atazanavir has the lowest propensity to increase total cholesterol levels."
        },
        {
          "id": 2,
          "text": "Tipranavir is used in sub-therapeutic doses as a pharmacodynamic booster in cART."
        },
        {
          "id": 3,
          "text": "Indinavir can cause nephrolithiasis when adequate hydration is not maintained."
        },
        {
          "id": 4,
          "text": "Ritonavir is a potent inhibitor of the CYP3A4 isoform of P450 & may alter levels of drugs."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of <strong>adverse effects</strong> of&nbsp;gastrointestinal tolerance and fat redistribution due to&nbsp;<strong>protease inhibitors</strong>. HAART therapy includes this class of drugs along with 2 nucleoside reverse transcriptase inhibitors +/- NNRTIs.&nbsp;<strong>Ritonavir,&nbsp;</strong>not tipranavir, is used in <strong>sub-therapeutic</strong> <strong>doses</strong> as a pharmacodynamic booster of other protease inhibitors in cART.</p>\n<p>This is because ritonavir is a <strong>potent inhibitor </strong>of the<strong> CYP3A4</strong> isoform of P450. It inhibits their CYP3A-mediated metabolism and permits the use of lower doses of other protease inhibitors. Nelfinavir&nbsp;is the only protease inhibitor&nbsp;not boosted&nbsp;by ritonavir.</p>\n<p><strong>Indinavir</strong> is notable for its tendency to precipitate in the urinary tract, causing <strong>nephrolithiasis</strong>, unless the patient maintains a high state of hydration.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF6054",
      "difficulty": "medium"
    },
    {
      "text": "An AIDS patient on treatment with  AZT, lamivudine, indinavir, ketoconazole, and cotrimoxazole, develops breast hypertrophy, central adiposity, hyperlipidemia, insulin resistance, and nephrolithiasis. Which of the following drugs could have caused these?",
      "choices": [
        {
          "id": 1,
          "text": "Azidothymidine"
        },
        {
          "id": 2,
          "text": "Indinavir"
        },
        {
          "id": 3,
          "text": "Ketoconazole"
        },
        {
          "id": 4,
          "text": "Lamivudine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Indinavir</strong>, a protease inhibitor, is the most likely cause for these adverse effects.</p>\n<p>Patients being treated with <strong>protease</strong> inhibitors (e.g., indinavir) develop a syndrome involving the <strong>derangement</strong> of <strong>lipid metabolism.</strong> This causes changes in body fat distribution. Type 2 diabetes mellitus has also been reported. This is called&nbsp;<strong>HIV/HAART-associated lipodystrophy.</strong></p>\n<p>Indinavir can also <strong>precipitate</strong> in the urinary tract, causing <strong>nephrolithiasis,</strong> unless the patient is maintained in a high state of hydration.</p>\n<p>Indinavir binds to the site of HIV-1 protease activity and inhibits cleavage of viral gag-pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, non-infectious viral particles.</p>\n<p><strong>Option A:</strong> Azidothymidine or&nbsp;zidovudine, is a nucleoside reverse transcriptase inhibitor.&nbsp;Chronic zidovudine administration has been associated with nail hyperpigmentation.&nbsp;</p>\n<p><strong>Option C</strong>: Ketoconazole is an antifungal agent that inhibits fungal ergosterol synthesis. Its adverse effects include liver dysfunction and testosterone synthesis inhibition leading to gynecomastia.&nbsp;</p>\n<p><strong>Option D</strong>: Lamivudine is a nucleoside reverse transcriptase inhibitor.&nbsp;It is one of the least toxic antiretroviral drugs. Neutropenia, headache, and nausea have been reported at higher-than-recommended doses.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6209",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a monoclonal antibody approved for use in the treatment of HIV?",
      "choices": [
        {
          "id": 1,
          "text": "Bevacizumab"
        },
        {
          "id": 2,
          "text": "Ibalizumab"
        },
        {
          "id": 3,
          "text": "Panitumumab"
        },
        {
          "id": 4,
          "text": "Pembrolizumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\"><strong>Ibalizumab</strong> is an <strong>anti-CD4 monoclonal antibody</strong> approved for use in the treatment of&nbsp;<strong>multidrug-resistant HIV-1.&nbsp;</strong>It is administered <strong>intravenously.</strong></p>\n<p>It acts as an entry inhibitor. It blocks HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 cells. It also interferes with post-attachment steps required for the entry of HIV-1 virus particles into host cells and thus prevents the viral transmission that occurs via cell-cell fusion.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1008",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an integrase inhibitor indicated in the treatment of patients with HIV?",
      "choices": [
        {
          "id": 1,
          "text": "Lopinavir"
        },
        {
          "id": 2,
          "text": "Abacavir"
        },
        {
          "id": 3,
          "text": "Raltegravir"
        },
        {
          "id": 4,
          "text": "Ritonavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"p-rich_text_section\">\n<p>The<strong><span data-preserver-spaces=\"true\"> integrase inhibitor</span></strong><span data-preserver-spaces=\"true\">&nbsp;indicated in the treatment of HIV is&nbsp;</span><strong><span data-preserver-spaces=\"true\">raltegravir</span></strong><span data-preserver-spaces=\"true\">. </span></p>\n<p><span data-preserver-spaces=\"true\">It inhibits the catalytic activity of the HIV-encoded integrase and&nbsp;</span><strong>prevents</strong> the <strong>integration</strong> of <strong>virus DNA</strong> in<strong>to</strong> the <strong>host chromosome</strong><span data-preserver-spaces=\"true\"><strong>.</strong> It is eliminated primarily by glucuronidation by UGT1A1.</span></p>\n<p><span data-preserver-spaces=\"true\">The other two FDA-approved integrase inhibitors are&nbsp;</span><strong><span data-preserver-spaces=\"true\">elvitegravir</span></strong><span data-preserver-spaces=\"true\">&nbsp;(EVG) and&nbsp;</span><strong><span data-preserver-spaces=\"true\">dolutegravir</span></strong><span data-preserver-spaces=\"true\">&nbsp;(DTG).</span></p>\n<p><span data-preserver-spaces=\"true\">Options A and D: Lopinavir and ritonavir are protease inhibitors.</span></p>\n<p><span data-preserver-spaces=\"true\">Option B: Abacavir is a nucleoside reverse transcriptase inhibitor.</span></p>\n<p><span data-preserver-spaces=\"true\">Note:&nbsp;&nbsp;</span><strong><span data-preserver-spaces=\"true\">Dolutegravir&nbsp;</span></strong><span data-preserver-spaces=\"true\">(DTG) is recommended as the preferred third drug for HIV post-exposure prophylaxis as per the recent MOHFW Jan 2020 guideline, in line with WHO.</span></p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA approved Dolutegravir tablets and suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg who have never been treated for HIV or who have been treated, but not with an integrase inhibitor class of drug.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:895,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16777215},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0}\">The FDA approved dolutegravir tablets and suspension for the treatment of HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg who have never been treated for HIV or who have been treated, but not with an integrase inhibitor class of drug.</span></p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA approved Dolutegravir tablets and suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg who have never been treated for HIV or who have been treated, but not with an integrase inhibitor class of drug.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:895,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16777215},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0}\">WHO recently recommended<strong> long-acting Cabotegravir</strong>, an HIV integrase strand transfer inhibitor may be offered as a <strong>HIV prevention</strong> option for people at substantial risk of HIV infection. It is an <strong>IM injectable</strong> form of <strong>pre-exposure prophylaxis</strong> that has been shown to be highly effective at reducing the risk of HIV acquisition. The first<strong> 2 injections</strong> were administered <strong>4 weeks apart</strong>, followed thereafter by an <strong>injection every 8 weeks</strong>.</span>&nbsp;</p>\n</div><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6444",
      "difficulty": "easy"
    }
  ]
}